Eton Pharmaceuticals Announces FDA Approval of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) as Replacement Therapy in Pediatric Patients with Adrenocortical Insufficiency
29 sept. 2020 18h50 HE
|
Eton Pharmaceuticals
-ALKINDI SPRINKLE is the first and only FDA-approved granular hydrocortisone formulation for adrenocortical insufficiency specifically designed for children -Eton expects ALKINDI SPRINKLE to be...
Eton Pharmaceuticals Provides Update on the FDA Review of EM-100
16 sept. 2020 09h00 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
Eton Pharmaceuticals Announces Appointment of Ingrid Hoos as Senior Vice President of Scientific Affairs
31 août 2020 08h00 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
Eton Pharmaceuticals Announces Second Quarter 2020 Financial Results
12 août 2020 08h30 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
Eton Pharmaceuticals Provides Update on the FDA Review of EM-100
11 août 2020 09h00 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
Eton Pharmaceuticals to Report Second Quarter Financial Results on Wednesday, August 12, 2020
04 août 2020 16h10 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
Eton Pharmaceuticals Submits New Drug Application to the FDA for Zonisamide Oral Suspension (ET-104)
30 juil. 2020 08h00 HE
|
Eton Pharmaceuticals
- Application Submitted for the Treatment of Partial Seizures in Epilepsy Patients - Eton’s Patent-Pending Product Addresses Significant Unmet Need for a Liquid Formulation of Zonisamide -...
Eton Pharmaceuticals Submits New Drug Application to the FDA for Orphan Drug Dehydrated Alcohol Injection (DS-100)
27 juil. 2020 07h30 HE
|
Eton Pharmaceuticals
-Granted Orphan Drug Designation by the FDA for the Treatment of Methanol Poisoning -Since the Start of COVID-19, the FDA has Recalled More Than 75 Contaminated Hand Sanitizers Due to Risk of...
Eton Pharmaceuticals Announces First Quarter 2020 Financial Results
14 mai 2020 16h02 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., May 14, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
Eton Pharmaceuticals Confirms First-to-File Patent Challenge on Elcys (Cysteine Hydrochloride Injection)
07 mai 2020 08h00 HE
|
Eton Pharmaceuticals
-Eton confirms first-to-file ANDA referencing Exela Pharma Sciences’ Elcys product -Eton plans to file Post Grant Reviews in the U.S. Patent & Trademark Office challenging the validity of Exela’s...